Share Price:

APNASPENAspen Pharmacare Hldgs21798-52 (-0.24%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Stephen Saad’s Aspen: From JSE newcomer to R150bn valuation in 16 years

In 1998, Stephen Saad and Gus Attridge took their ambitions public through the reverse takeover by their year-old business into JSE-listed Medhold. A year later they pulled off a R2.4bn hostile takeover of the well resourced but poorly managed SA Druggists. And the rest is history. Now a multinational corporation, last week Aspen delivered another sparkling… Continue reading Stephen Saad’s Aspen: From JSE newcomer to R150bn valuation in 16 years

Aspen’s revenue soars by 53% to R29.5 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2014. GROUP PERFORMANCE Revenue increased by 53% to R29.5 billion. Operating profit rose by 47% to R7.4 billion. Normalised headline earnings, being… Continue reading Aspen’s revenue soars by 53% to R29.5 billion

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.